The latest FDA drug approvals: What you need to know

Drug Topics

Volumn 156, Issue 3, 2012, Pages 24-

  Pham, Trinh ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ARCAPTA NEOINHALER; AZILSARTAN MEDOXOMIL; BASILIXIMAB; BELATACEPT; BELIMUMAB; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BOCEPREVIR; BRENTUXIMAB VEDOTIN; CEFTAROLINE FOSAMIL; CORIFACT; CORTICOSTEROID; CRIZOTINIB; DABIGATRAN ETEXILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERIBULIN; GABAPENTIN ENACARBIL; ICATIBANT; IPILIMUMAB; LURASIDONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; PREDNISONE; RILPIVIRINE; ROFLUMILAST; TELAPREVIR; TESAMORELIN; TICAGRELOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VILAZODONE;

ABDOMINAL PAIN; ACNE; ACUTE CORONARY SYNDROME; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANDROGEN SYNTHESIS; ANEMIA; ANGIONEUROTIC EDEMA; ANORECTAL DISEASE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BLEEDING; BREAST CANCER; BRONCHITIS; CALCIUM BLOOD LEVEL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; ENDOCRINE DISEASE; ENTEROCOLITIS; ERYTHEMA; EYE DISEASE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTRITIS; GENE TRANSLOCATION; GLUCOSE BLOOD LEVEL; GRAFT DYSFUNCTION; HEART ARRHYTHMIA; HEART INFARCTION; HEMOPHILIA A; HEMORRHOID; HEPATITIS; HEPATITIS C; HODGKIN DISEASE; HORMONE SYNTHESIS; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTHERMIA; HYPOKALEMIA; INJECTION SITE REACTION; INSOMNIA; INTESTINE PERFORATION; JOINT DISCOMFORT; JOINT SWELLING; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIMB PAIN; LIPODYSTROPHY; LIVER CIRRHOSIS; LOADING DRUG DOSE; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR DEPRESSION; MELANOMA; METASTASIS POTENTIAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIGRAINE; MULTIPLE CYCLE TREATMENT; MUSCLE DISCOMFORT; NAUSEA; NEUROPATHY; NEUTROPENIA; NOCTURIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOSENSITIVITY DISORDER; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PRURITUS; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCHIZOPHRENIA; SCORPION; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN PAPILLOMA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROID FUNCTION TEST; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY TRACT INFECTION; UVEITIS; VISUAL DISORDER; VOMITING;

EID: 84858986976     PISSN: 00126616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. U.S. Food and Drug Administration. Department of Health and Human Services. FY 2011 Innovative Drug Approvals. November 2011. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM278358.pdf. Accessed February 3, 2012.
2. Zytiga label. FDA website. Published April 28, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf. Accessed February 1, 2012.
3. Adcetris label. FDA website. Published January 13, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125388s0005lbl.pdf. Accessed February 1, 2012.
4. Xalkori label. FDA website. Published August 26, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf. Accessed February 1, 2012.
5. Halaven label. FDA website. Published November 15, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf. Accessed February 1, 2012.
6. Yervoy label. FDA website. Published March 25, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf. Accessed February 1, 2012.
7. Caprelsa label. FDA website. Published June 22, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s001lbl.pdf. Accessed February 1, 2012.
8. Zelboraf label. FDA website. Published August 17, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf. Accessed February 1, 2012.
9. Corifact label. FDA website. Published February 15, 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM244157.pdf. Accessed February 2, 2012.
10. Victrelis label. FDA website. Published May 13, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf. Accessed February 2, 2012.
11. Incivek label. FDA website. Published May 23, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf. Accessed February 2, 2012.
12. Firazyr label. FDA website. Published August 25, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf. Accessed February 2, 2012.
13. Nulojix label. FDA website. Published June 15, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125288s0000lbl.pdf. Accessed February 2, 2012.
14. Teflaro label. FDA website. Published June 29, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf. Accessed February 2, 2012.
15. Pradaxa label. FDA website. Published January 17, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s009lbl.pdf. Accessed February 2, 2012.
16. Brilinta label. FDA website. Published July 20, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022433s000lbl.pdf. Accessed February 2, 2012.
17. Anascorp label. FDA website. Published July 27, 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM266725.pdf. Accessed February 2, 2012.
18. Edlin M. Almost half of new molecular entities approved in 2011 considered significant therapeutic advances. Formulary. 2012;47:26-38.
19. Benlysta label. FDA website. Published March 10, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125370s0000lbl.pdf. Accessed February 2, 2012.